Charcot-Marie-Tooth Disease Clinical Trial
Official title:
The Impact of Charcot-Marie-Tooth Disease in the Real World
An observational, non-interventional registry study to collect real-world data from people living with Charcot-Marie-Tooth disease (CMT) and its treatment, which will be available to researchers to further the knowledge of Charcot-Marie-Tooth disease and improve patient care.
Status | Recruiting |
Enrollment | 2500 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: (*) Aged 18 years and over (*) Diagnosed with any stage and any subtype of Charcot-Marie-Tooth disease (*) Resident in France, Germany, Italy, Spain, the UK, or the USA (*) Have a National Health Service (NHS) or Community Health Index (CHI) number, or equivalent (*) Willing to use their own smartphone Exclusion Criteria: (*) No specific exclusion criteria. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Vitaccess Ltd | London |
Lead Sponsor | Collaborator |
---|---|
Vitaccess Ltd | ACMT-Rete per la malattia di Charcot-Marie-Tooth OdV, Charcot-Marie-Tooth Association, Charcot-Marie-Tooth UK, CMT France, Federación Española de Enfermedades Neuromusculares, Hereditary Neuropathy Foundation, Pharnext SA |
United Kingdom,
Thomas FP, Saporta M, Attarian S, Sevilla T, Mascaro RS, Fabrizi GM, Genovese F, Gray A, Bull S, Tanesse D, Rego M, Moore A, Hollett C, Monteiro K, Paoli X, Llewellyn S, Larkin M, Boutalbi Y. Patient-reported impact of Charcot-Marie-Tooth disease: protocol for a real-world digital lifestyle study. Neurodegener Dis Manag. 2021 Feb;11(1):21-33. doi: 10.2217/nmt-2020-0044. Epub 2020 Oct 22. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | EuroQoL 5-dimension 5-level (EQ-5D-5L) | The EQ-5D-5L comprises two parts - the EQ-5D-5L descriptive system and the EQ Visual Analogue Scale (EQ VAS).
The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems - i.e., higher scores represent worse health). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The EQ VAS records the respondent's self-rated health on vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. Higher scores represent better self-perceived health. |
Throughout study completion, up to 62 months | |
Secondary | Work Limitations Questionnaire (WLQ) | The WLQ measures the impact of CMT on participants' work ability and productivity. The measure comprises 25 items that ask respondents to rate their level of difficulty or ability to perform specific job demands, aggregated into four domains: time management, physical demands, mental-interpersonal demands, and output demands. Domain scores range from 0 to 100 and the recall period is the previous 2 weeks. WLQ domain scores can be converted into an estimate of productivity loss using an algorithm. | Throughout study completion, up to 62 months | |
Secondary | Brief Fatigue Inventory (BFI) | The BFI assesses the fatigue severity in patients with CMT. The measure comprises 10 items, although the first item asks about usual fatigue over the past week (with the respondent answering "yes" or "no") and is not included in the overall score. The remaining nine items assess general fatigue within two subscales: fatigue severity (three items), and the impact of fatigue on daily functioning (six items). The measure uses a 10-point numeric rating scale, and a recall period of 24 hours. A global fatigue score can be calculated by averaging all nine items. | Throughout study completion, up to 62 months | |
Secondary | Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity 3a and Interference 8a | The PROMIS pain intensity measure includes two items that assess pain intensity over the last 7 days (average and worst pain), and one for pain intensity "right now"; each scores using a 5-point scale. Scores range from 2-10. Higher scores represent worst pain. This measure is generic rather than disease-specific.
The PROMIS pain interference measure assesses the extent to which pain hinders engagement with social, cognitive, emotional, physical and recreational activities, sleep, and enjoyment in life over the last 7 days using a 5-point scale. Scores range from 8-40. Higher scores represent worse interference. This measure is generic rather than disease-specific. |
Throughout study completion, up to 62 months | |
Secondary | Bespoke questionnaire for this study | Two cramp-specific items were developed for inclusion in the survey, measuring cramp frequency and intensity. The cramp frequency item asks "In the past 7 days, how many days did you experience cramp?" and has five possible responses: had no cramp, 1-2 days, 3-4 days, 5-6 days, every day. The cramp intensity item asks "In the past 7 days, how intense was your cramp at its worst?" and has five possible responses: had no cramp, mild, moderate, severe, very severe. Higher scores on both items represent greater cramp frequency and intensity respectively. | Throughout study completion, up to 62 months | |
Secondary | Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance 8a | The PROMIS sleep disturbance measure assesses self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep over the last 7 days using a 5-point scale. Scores range from 8-40. Higher scores represent worse sleep disturbance. This measure is generic rather than disease-specific. | Throughout study completion, up to 62 months | |
Secondary | Falls Efficacy Scale - International (FES-I) | The FES-I measures the level of concern about falling during social and physical activities inside and outside hte home, whether or not the person actually does the activity. The "usual" level of concern is measured on a four-point Likert scale (1 = not at all concerned to 4 = very concerned), with a time frame of "usual". Scores range from 16-64. Higher scores represent greater concern about falling. | Throughout study completion, up to 62 months | |
Secondary | Lower Extremity Function Scale (LEFS) | The LEFS evaluates difficulties because of lower limb problems in 20 activities, including work/school activities, hobbies, moving around the home, dressing, lifting, standing, sitting, walking, and running. The level of difficulty is assessed for "today" using a 5-point Likert scale (0 = extreme difficulty or unable to perform activity; 5 = No difficulty). Lower scores represent greater difficulties experience because of lower limb problems. | Throughout study completion, up to 62 months | |
Secondary | QuickDash (Disabilities of the Arm, Shoulder and Hand) | The QuickDash measure uses 11 items to measure physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb. Six questions relate to the ability to perform six activities over the last week, ranging from opening a jar, carrying, washing and recreational activities; two questions relate to impact on social and daily activities; two questions ask the person to rate the severity of pain and tingling in the arms, shoulder or hand, and one question relates to the effects of pain on sleep. All questions are rated 1-5 (no difficulty/none/not at all through to unable/extreme difficulty). Scores range from 11-55. Higher scores represent greater difficulties with physical function and symptoms. | Throughout study completion, up to 62 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06203093 -
Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for iPSC Generation and Biobanking
|
||
Recruiting |
NCT02979145 -
Charcot-Marie-Tooth Disease (CMT) Infant Scale (INC-6611)
|
N/A | |
Terminated |
NCT03254199 -
A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps.
|
Phase 2 | |
Completed |
NCT02011204 -
Study of Electrical Impedance Myography (EIM) in ALS
|
N/A | |
Completed |
NCT00149045 -
Follow up and Observation of Charcot Marie Tooth Disease in Families
|
N/A | |
Completed |
NCT04786522 -
Irisin Levels in Patients With Charcot-Marie-Tooth (CMT) Disease
|
||
Recruiting |
NCT05011006 -
NT-3 Levels and Function in Individuals With CMT
|
||
Recruiting |
NCT05902351 -
Natural History Study for Charcot Marie Tooth Disease
|
||
Terminated |
NCT03943290 -
Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)
|
Phase 2 | |
Active, not recruiting |
NCT04762758 -
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients
|
Phase 3 | |
Completed |
NCT02788734 -
Patient Reported Outcomes Measures (PROM) in Carpal Tunnel Therapies in Patients With Inherited Neuropathies
|
N/A | |
Recruiting |
NCT02532244 -
Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases
|
||
Terminated |
NCT05827419 -
Hearing and Balance Disorders in Peripheral Neuropathy
|
||
Terminated |
NCT03124459 -
Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease
|
Phase 2 | |
Terminated |
NCT03810508 -
A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J)
|
||
Recruiting |
NCT04010188 -
A Registered Cohort Study on Charcot-Marie-Tooth Disease
|
||
Completed |
NCT00271635 -
Ascorbic Acid Treatment in CMT1A Trial (AATIC)
|
Phase 2 | |
Completed |
NCT03715283 -
Change in MUNIX in Patients With CMT1A Undergoing a Home Ankle Strengthening Program Versus Standard of Care
|
N/A | |
Completed |
NCT02001038 -
Survey of Current Management of Orthopaedic Complications in CMT Patients
|
N/A | |
Not yet recruiting |
NCT01289704 -
Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A)
|
Phase 2/Phase 3 |